🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Early Detection and IntervenTion in Heart Failure

RecruitingNAAges 65 Years - anyAllUniversity Hospital, Basel, Switzerland
NCT07731490 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Heart failure (HF) occurs when the heart is no longer able to pump blood effectively throughout the body. This leads to symptoms that gradually worsen over time and are often mistaken for normal signs of aging. Because of its insidious onset, early detection is challenging. Both patients and healthcare professionals are often insufficiently aware of the early signs and symptoms of HF, resulting in delayed diagnosis. Consequently, timely initiation of treatments that could slow disease progression, improve quality of life, and reduce hospitalizations is often missed. Although a simple blood test measuring NT-proBNP levels can facilitate the early diagnosis of HF, it is not routinely used in clinical practice. The aim of this study is to evaluate whether a combined strategy for the early diagnosis and treatment of HF can reduce hospitalizations. This strategy includes: 1. increasing awar

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * General consent (GC) has not been rejected. * Age ≥ 65 years. * Elective percutaneous coronary intervention\* (PCI), pulmonary vein isolation\* (PVI), pacemaker implantation\* (PM, no cardiac resynchronisation), transcatheter aortic valve intervention\* (TAVI), major non-cardiac surgery\* or presenting with tachyarrhythmia to the emergency department (ED) (without a diagnosis of HF within 24h). * Exclusion criteria are assessed on day 1 after the procedure Exclusion Criteria: * Systolic blood pressure ≤ 95 mmHg * Estimated glomerular filtration rate (GFR) \<30 mL/min/1.73 m2. * Dementia documented in the medical history. * Metastatic cancer in the medical history. * Previously enrolled in this study. * Known HF. * Known allergies, hypersensitivity, or intolerance to SGLT2 Inhibitors / Loop Diuretics / MRA or is excipients. * Non-resident in the country of the recruiting site * Incapacity of the patient to make judgements * Patients not hospitalized overnight * Patients requiring intensive care unit (ICU) or intermediate care (IMC) stay beyond 11:00 a.m. on the first postoperative day or any post-interventional stroke unit stay until 8:00 a.m. on the first postoperative day. * Patients died prior to postinterventional day 1 (8:00 a.m.) * Severe aortic or mitral stenosis
💊

What it tests

  • Intervention bundle comprising increased awareness, early diagnostics, and early treatment to improve HF prognosis.
📍

Where

21 sites
Universitätsklinik für Innere Medizin II
Vienna, Austria
Queen Giovanna University Hospital
Sofia, Bulgaria
University Hospital Freiburg-Bad Krozingen
Freiburg im Breisgau, Germany
Universitätsklinikum der Ruhr-Universität Bochum
Herne, Germany
Herzzentrum Leipzig, Klinik für Innere Medizin/Kardiologie
Leipzig, Germany
University Hospital Pisa
Pisa, Italy
Erasmus MC Rotterdam
Rotterdam, Netherlands
Konkuk University Medical Center
Seoul, South Korea

…and 13 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy